Should male children be vaccinated against human papillomavirus?
¿Se debe vacunar contra el virus del papiloma humano a niños varones?
DOI:
https://doi.org/10.15446/revfacmed.v65n3.61313Descargas
letter to the editor
DOI: https://doi.org/10.15446/revfacmed.v65n3.61313
Should male children be vaccinated against human papillomavirus?
¿Se debe vacunar contra el virus del papiloma humano a niños varones?
Received: 29/11/2016. Accepted: 07/02/2017.
Gerardo Sebastián Legua-Pérez1 • José Fidel Ramos-Canevaro1
1 Universidad Nacional San Luis Gonzaga de Ica - Faculty of Human Medicine Daniel Alcides Carrión - Ica - Perú.
Corresponding author: Gerardo Sebastián Legua-Pérez. Faculty of Human Medicine Daniel Alcides Carrión, Universidad Nacional San Luis Gonzaga de Ica. Avenida Daniel Alcides Carrión s/n. Phone number: +51 941370951. Ica. Perú. Email: leguasebastian@gmail.com.
Legua-Pérez G, Ramos-Canevaro J. Should male children be vaccinated against human papillomavirus? Rev. Fac. Med. 2017;65(3):537. English. doi: https://doi.org/10.15446/revfacmed.v65n3.61313.
Legua-Pérez GS, Ramos-Canevaro JF. [¿Se debe vacunar contra el virus del papiloma humano a niños varones?] Rev. Fac. Med. 2017;65(3):537. English. doi: https://doi.org/10.15446/revfacmed.v65n3.61313.
Dear Editor:
Human papillomavirus (HPV) is the main risk factor for the development of cervical cancer in women and other types of malignancies in men, including penile, oropharyngeal and perianal cancer. These neoplasms take longer to be detected because the infection is asymptomatic and silent in men (1,2).
The serotypes with the highest infection frequency and greater virulence in both males and females are 16 and 18 (3). It is estimated that HPV infection has a prevalence of 7.5% in Peruvian women with normal cytological studies. Subtypes 16 and 18 have a prevalence of 3.8% in this population, and 68.3% in women with cervical cancer (4).
Between 2006 and 2011, the incidence of cervical neoplasms was 16 374 cases, with a mortality rate of 1 603 cases by 2011. In 2008, 35 489 healthy life years and 20 691 years of life lost due to premature mortality were observed (5). Furthermore, in 2014, there was an incidence of 310 oral cavity cancer cases, 72 anal cancer cases, and 42 penile cancer cases according to the National Institute of Neoplastic Diseases (INEN by its acronym in Spanish) in Peru (6). The US Food and Drug Administration (FDA) estimates that by 2020 this virus will be responsible for the incidence of penile, oropharyngeal and perianal cancers, which will be similar to or greater than the current incidence of cervical cancer, and would increase health costs for the treatment of this type of pathologies (7).
Currently, there is a tetravalent HPV vaccine that provides protection against serotypes 6, 11, 16 and 18. It is not only accessible, safe and effective, but also has few adverse effects on the male population, decreases the recurrence of anogenital cancer, reduces the incidence of intraepithelial neoplasm and persistent anal infection, and is effective in preventing external genital lesions (7).
A non-temporary vaccine is used in the United States, which, besides covering the aforementioned serotypes, protects against 31, 33, 45, 52 and 58, considered to be high risk factors for anogenital cancer. The FDA recommends its use in men —who are offered protection against genital warts and cancerous and precancerous anal lesions (1,8)— and women aged between 9 and 26.
To stop a virus from spreading, we must act on the vector, which in the case of HPV is men. Therefore, including vaccination against HPV for both men and women aged between 9 and 13 years in public health policies and immunization strategies is strongly advised.
References
1.Aranda-Flores CE. Infección por el virus del papiloma humano en varones. Ginecol Obstet Mex. 2015;83(11):697-706.
2.Brebi P, Hartley R, Ili C, Roa JC, Sánchez R. Infección por el virus del papiloma humano en el hombre y su relación con el cáncer: estado actual y prospectivas. Rev Int Androl. 2013;11(1):25-30.
3.Silva R, León D, Brebi P, Ili C, Roa JC, Sánchez R. Diagnóstico de la infección por virus papiloma humano en el hombre. Rev Chilena Infectol. 2013;30(2):186-92.
4.WHO/ICO Information Centre on HPV and Cervical Cancer. Human papillomavirus and related cancers in Peru. Summary report 2010. Barcelona: HPV Information Centre; 2010 [cited 2017 Apr 27]. Available from: https://goo.gl/tqeWfY.
5.Perú. Ministerio de Salud. Dirección de Epidemiología. Análisis de la situación del cáncer en el Perú, 2013. Lima: Ministerio de Salud; 2013.
6.Perú. Instituto Nacional de Enfermedades Neoplásicas. Datos epidemiológicos. Casos nuevos de cáncer registrados en el INEN, periodo 2000-2014. Lima: INEN; 2015 [cited 2017 Apr 27]. Available from: https://goo.gl/OIx2yo.
7.Estados Unidos de América. Centros para el Control y la Prevención de Enfermedades. La vacuna contra el VPH también se recomienda para los niños varones. Atlanta: CDC; 2015 [cited 2017 Apr 27]. Available from: https://goo.gl/dJf3Jd.
8.Merck & Co., Inc. Patient information about GARDASIL® 9 (pronounced “gard-Ah-sill nīn”) (Human Papillomavirus 9-valent Vaccine, Recombinant). Kenilworth, NJ: Merck & Co., Inc.; 2016 [cited 2017 Apr 27]. Available from: https://goo.gl/sUKGfi.
Iván “Ivanquio” Benavides
“El niño vacío” – 013
Técnica: tinta, color digital
Recibido: 29 de noviembre de 2016; Aceptado: 7 de febrero de 2017
Dear Editor:
Human papillomavirus (HPV) is the main risk factor for the development of cervical cancer in women and other types of malignancies in men, including penile, oropharyngeal and perianal cancer. These neoplasms take longer to be detected because the infection is asymptomatic and silent in men 1,2.
The serotypes with the highest infection frequency and greater virulence in both males and females are 16 and 18 3. It is estimated that HPV infection has a prevalence of 7.5% in Peruvian women with normal cytological studies. Subtypes 16 and 18 have a prevalence of 3.8% in this population, and 68.3% in women with cervical cancer 4.
Between 2006 and 2011, the incidence of cervical neoplasms was 16 374 cases, with a mortality rate of 1 603 cases by 2011. In 2008, 35 489 healthy life years and 20 691 years of life lost due to premature mortality were observed 5. Furthermore, in 2014, there was an incidence of 310 oral cavity cancer cases, 72 anal cancer cases, and 42 penile cancer cases according to the National Institute of Neoplastic Diseases (INEN by its acronym in Spanish) in Peru 6. The US Food and Drug Administration (FDA) estimates that by 2020 this virus will be responsible for the incidence of penile, oropharyngeal and perianal cancers, which will be similar to or greater than the current incidence of cervical cancer, and would increase health costs for the treatment of this type of pathologies 7.
Currently, there is a tetravalent HPV vaccine that provides protection against serotypes 6, 11, 16 and 18. It is not only accessible, safe and effective, but also has few adverse effects on the male population, decreases the recurrence of anogenital cancer, reduces the incidence of intraepithelial neoplasm and persistent anal infection, and is effective in preventing external genital lesions 7.
A non-temporary vaccine is used in the United States, which, besides covering the aforementioned serotypes, protects against 31, 33, 45, 52 and 58, considered to be high risk factors for anogenital cancer. The FDA recommends its use in men -who are offered protection against genital warts and cancerous and precancerous anal lesions 1,8- and women aged between 9 and 26.
To stop a virus from spreading, we must act on the vector, which in the case of HPV is men. Therefore, including vaccination against HPV for both men and women aged between 9 and 13 years in public health policies and immunization strategies is strongly advised.
References
Referencias
Aranda-Flores CE. Infección por el virus del papiloma humano en varones. Ginecol Obstet Mex. 2015;83(11):697-706.
Brebi P, Hartley R, Ili C, Roa JC, Sánchez R. Infección por el virus del papiloma humano en el hombre y su relación con el cáncer: estado actual y prospectivas. Rev Int Androl. 2013;11(1):25-30.
Silva R, León D, Brebi P, Ili C, Roa JC, Sánchez R. Diagnóstico de la infección por virus papiloma humano en el hombre. Rev Chilena Infectol. 2013;30(2):186-92.
WHO/ICO Information Centre on HPV and Cervical Cancer. Human papillomavirus and related cancers in Peru. Summary report 2010. Barcelona: HPV Information Centre; 2010 [cited 2017 Apr 27]. Available from: https://goo.gl/tqeWfY.
Perú. Ministerio de Salud. Dirección de Epidemiología. Análisis de la situación del cáncer en el Perú, 2013. Lima: Ministerio de Salud; 2013.
Perú. Instituto Nacional de Enfermedades Neoplásicas. Datos epidemiológicos. Casos nuevos de cáncer registrados en el INEN, periodo 2000-2014. Lima: INEN; 2015 [cited 2017 Apr 27]. Available from: https://goo.gl/OIx2yo.
Estados Unidos de América. Centros para el Control y la Prevención de Enfermedades. La vacuna contra el VPH también se recomienda para los niños varones. Atlanta: CDC; 2015 [cited 2017 Apr 27]. Available from: https://goo.gl/dJf3Jd.
Merck & Co., Inc. Patient information about GARDASIL® 9 (pronounced “gard-Ah-sill nīn”) (Human Papillomavirus 9-valent Vaccine, Recombinant). Kenilworth, NJ: Merck & Co., Inc.; 2016 [cited 2017 Apr 27]. Available from: https://goo.gl/sUKGfi.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Derechos de autor 2017 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
Derechos de autor
Los autores deben aceptar transferir a la Revista de la Facultad de Medicina los derechos de autor de los artículos publicados. La editorial tiene el derecho del uso, reproducción, transmisión, distribución y publicación en cualquier forma o medio. Los autores no podrán permitir o autorizar el uso de la contribución sin el consentimiento escrito de la revista. Estos archivos están disponibles en https://goo.gl/EfWPdX y https://goo.gl/6zztk4 y deben cargarse en el paso 4 del envío OJS (archivos complementarios).
La carta de cesión de derechos de autor y la de responsabilidad de autoría deben ser entregadas junto con el original.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).